ANI PHARMACEUTICALS INC Form SC 13G February 06, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

ANI PHARMACEUTICALS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

09065V302

(CUSIP Number)

12/31/13

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

o Rule 13d-1(c)

x Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 09065V302		13G
1.	Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only)
	FA Private Equity Fund IV, L.P.	
	36-4432547	
2.	Check the Appropriate Box if a Member of a (a) o (b) x	Group (See Instructions)
3.	SEC Use Only	
4.	Citizenship or Place of Organization DE	
	5.	Sole Voting Power 3,314,964
Number of Shares	6.	Shared Voting Power
Beneficially Owned by	0.	00,000
Each Reporting Person With	7.	Sole Dispositive Power 3,314,964
	8.	Shared Dispositive Power 00,000
9.	Aggregate Amount Beneficially Owned by E 3,314,964	ach Reporting Person
10.	Check if the Aggregate Amount in Row (9) E	excludes Certain Shares (See Instructions) o
11.	Percent of Class Represented by Amount in F 5.8%	Row (9)
12.	Type of Reporting Person (See Instructions) PN	

CUSIP No. 09065V302		13G
1.	Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only)	
	FA Private Equity Fund IV GmbH & Co.	Beteiligungs KG
	Foreign	
2.	Check the Appropriate Box if a Member of (a) o (b) x	f a Group (See Instructions)
3.	SEC Use Only	
4.	Citizenship or Place of Organization Germany	
	5.	Sole Voting Power 138,091
Number of Shares Beneficially Owned by Each Reporting	6.	Shared Voting Power 00,000
	7.	Sole Dispositive Power 138,091
Person With	8.	Shared Dispositive Power 00,000
9.	Aggregate Amount Beneficially Owned by 138.091	y Each Reporting Person
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
11.	Percent of Class Represented by Amount i 0.2%	in Row (9)
12.	Type of Reporting Person (See Instruction PN	s)

CUSIP No. 09065V302				13G
1.	Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only)			
	The Productivity Fund IV	Liquidating Trust		
	45-6899967			
2.	Check the Appropriate Bo (a) (b)	x if a Member of a G o x	roup (See Instructions)	
3.	SEC Use Only			
4.	Citizenship or Place of Or DE	ganization		
Number of	5.		Sole Voting Power 1,345,812	
Number of Shares Beneficially Owned by	6.		Shared Voting Power 00,000	
Each Reporting Person With	7.		Sole Dispositive Power 1,345,812	
	8.		Shared Dispositive Power 00,000	
9.	Aggregate Amount Benefi 1,345,812	cially Owned by Eac	h Reporting Person	
10.	Check if the Aggregate Ar	nount in Row (9) Exc	cludes Certain Shares (See Inst	tructions) o
11.	Percent of Class Represent 2.4%	ted by Amount in Ro	w (9)	
12.	Type of Reporting Person OO (Other)	(See Instructions)		

CUSIP No. 09065V302		13G
1.	Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only)	
	The Productivity Fund IV Advisors I	Fund Liquidating Trust
	45-6899983	
2.	Check the Appropriate Box if a Men (a) o (b) x	aber of a Group (See Instructions)
3.	SEC Use Only	
4.	Citizenship or Place of Organization DE	
	5.	Sole Voting Power 51,778
Number of Shares Beneficially Owned by Each Reporting Person With	6.	Shared Voting Power 00,000
	7.	Sole Dispositive Power 51,778
	8.	Shared Dispositive Power 00,000
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 51,778	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o	
11.	Percent of Class Represented by Amount in Row (9) 0.1%	
12.	Type of Reporting Person (See Instru OO (Other)	actions)

CUSIP No. 09065V302		13G
1.	Names of Reporting Persons I.R.S. Identification Nos. of Above	Persons (Entities Only)
	Tracy L. Marshbanks	
	###-##-####	
2.	Check the Appropriate Box if a Me (a) o (b) x	mber of a Group (See Instructions)
3.	SEC Use Only	
4.	Citizenship or Place of Organizatio United States	n
	5.	Sole Voting Power 8,310
Number of Shares	6	
Beneficially Owned by	6.	Shared Voting Power 4,850,645
Each Reporting Person With	7.	Sole Dispositive Power 8,310
	8.	Shared Dispositive Power 4,850,645
9.	Aggregate Amount Beneficially Ov 4,858,955	vned by Each Reporting Person
10.	Check if the Aggregate Amount in	Row (9) Excludes Certain Shares (See Instructions) o
11.	Percent of Class Represented by Amount in Row (9) 8.5%	
12.	Type of Reporting Person (See Inst IN	ructions)

Edgar Filing: ANI PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 09065V302

13G

Item 1.			
	(a)	Name of Issuer	
		ANI PHARMACEUTICA	
	(b)	Address of Issuer s Princi 210 Main Street West, Bar	-
		210 Main Street West, Ba	udelle, MIN 30025
Item 2.			
	(a)	Name of Person Filing	
		See Cover Pages, Item 1	
	(b)	•	office or, if none, Residence
		c/o First Analysis Corp.,	
		One S. Wacker Dr.	
		Suite 3900	
		Chicago, IL 60606	
	(c)	Citizenship	
		See Cover Pages, Item 4.	
	(d)	Title of Class of Securities	3
		Common Stock	
	(e)	CUSIP Number 09065V302	
		09003 \$ 302	
Item 3.	If this stateme	ent is filed pursuant to §§240.13d	-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
	(a)	0	Broker or dealer registered under section 15 of the Act (15 U.S.C.
			78o).
	(b)	0	Bank as defined in section $3(a)(6)$ of the Act (15 U.S.C. 78c).
	(c)	0	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	0	Investment company registered under section 8 of the Investment
			Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	0	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
	(f)	0	An employee benefit plan or endowment fund in accordance with
			§240.13d-1(b)(1)(ii)(F);
	(g)	0	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
	(h)	0	A savings associations as defined in Section 3(b) of the Federal
			Deposit Insurance Act (12 U.S.C. 1813);
	(i)	0	A church plan that is excluded from the definition of an investment
	(i)	o	company under section 3(c)(14) of the Investment Company Act of
			company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(i) (j)	0	company under section 3(c)(14) of the Investment Company Act of
			company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

Edgar Filing: ANI PHARMACEUTICALS INC - Form SC 13G

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

See Cover Pages, Iter	ns 5 through 11.	
(a)	Amount beneficially owned:	
(b)	Percent of class:	
(c)	Number of shares as to which th	he person has:
	(i)	Sole power to vote or to direct the vote
		1
	(ii)	Shared power to vote or to direct the vote
	(iii)	Sole power to dispose or to direct the disposition of
	(iv)	Shared power to dispose or to direct the disposition of .

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class. n/a

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

Instruction. Dissolution of a group requires a response to this item.

Item 6.	Ownership of More than Five Percent on Behalf of Another Person. Please see Exhibit I attached hereto.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. n/a
Item 8.	Identification and Classification of Members of the Group. Please see Exhibit I attached hereto.
Item 9.	Notice of Dissolution of Group. n/a

Edgar Filing: ANI PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 09065V302

13G

Item 10. Certification.

n/a

(a)The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

(b)The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

2/06/14 Date

/s/ Tracy L. Marshbanks Signature

Tracy L. Marshbanks Name/Title

FA PRIVATE EQUITY FUND IV, L.P. By: FA Private Equity Management IV, L.L.C., its General Partner

By: First Analysis Private Equity Management Company IV, L.L.C., its Managing Member
By: First Analysis Venture Operations and Research, L.L.C., its Managing Member
By: First Analysis Corporation, its Manager
By: Tracy L. Marsbhanks, Managing Director
FA PRIVATE EQUITY FUND IV GMBH & CO. BETEILIGUNGS KG
By: FA Private Equity Management IV, L.L.C., its Managing Limited Partner

By: First Analysis Private Equity Management Company IV, L.L.C., its Managing Member By: First Analysis Venture Operations and Research, L.L.C., its Managing Member By: First Analysis Corporation, its Manager

THE PRODUCTIVITY FUND IV LIQUIDATING TRUST By: First Analysis Management Company IV, L.L.C., its Trustee By: First Analysis Venture Operations and Research, L.L.C., Its Managing MemberBy: First Analysis Corporation, Its ManagerBy: Tracy L. Marsbhanks, Managing Director

THE PRODUCTIVITY FUND IV ADVISORS FUND LIQUIDATING TRUST

By: First Analysis Management Company IV, L.L.C., its Trustee By: First Analysis Venture Operations and Research, L.L.C., Its Managing Member By: First Analysis Corporation, Its Manager By: Tracy L. Marshbanks, Managing Director Tracy L. Marshbanks